Phase 1 Cutaneous Clinical Trials
69 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 69 trials
Recruiting
Phase 1Phase 2
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
Recurrent Mycosis FungoidesRefractory Mycosis FungoidesSezary Syndrome+5 more
City of Hope Medical Center78 enrolled4 locationsNCT03011814
Recruiting
Phase 1Phase 2
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Aggressive NK-cell LeukemiaLGLL - Large Granular Lymphocytic LeukemiaPrimary Cutaneous Gamma-Delta T-Cell Lymphoma+10 more
Dren Bio200 enrolled37 locationsNCT05475925
Recruiting
Phase 1Phase 2
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Melanoma+10 more
National Cancer Institute (NCI)16 enrolled26 locationsNCT05896839
Recruiting
Phase 1
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
SLE (Systemic Lupus)Diffuse Cutaneous Systemic SclerosisSystemic Sclerosis+4 more
CRISPR Therapeutics80 enrolled14 locationsNCT06925542
Recruiting
Phase 1
Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
Unresectable Head and Neck Squamous Cell CarcinomaStage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8+27 more
National Cancer Institute (NCI)39 enrolled1 locationNCT07156227
Recruiting
Phase 1
US Zamto-cel Autoimmune Diseases
Systemic Lupus ErythematosusDiffuse Cutaneous Systemic SclerosisSystemic Sclerosis (SSc)+1 more
Miltenyi Biomedicine GmbH48 enrolled1 locationNCT06708845
Recruiting
Phase 1Phase 2
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic MelanomaPathologic Stage IV Cutaneous Melanoma AJCC v8+1 more
Kari Kendra24 enrolled1 locationNCT05588453
Recruiting
Phase 1
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Triple-Negative Breast CancerPancreatic CancerMelanoma+7 more
Memgen, Inc.40 enrolled2 locationsNCT05076760
Recruiting
Phase 1
Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
Advanced Solid TumorCutaneous MelanomaUveal Melanoma, Metastatic
MonTa Biosciences ApS106 enrolled5 locationsNCT04855435
Recruiting
Phase 1
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Myelodysplastic SyndromeB-cell Non Hodgkin LymphomaRefractory Acute Myeloid Leukemia+16 more
Mayo Clinic99 enrolled2 locationsNCT03017820
Recruiting
Phase 1Phase 2
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Colorectal, CancerCutaneous MelanomaOther Solid Tumors+1 more
IDEAYA Biosciences336 enrolled15 locationsNCT03947385
Recruiting
Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
Esophageal Squamous Cell CarcinomaCutaneous Squamous Cell CancerBladder Cancer+8 more
EvolveImmune United, Inc160 enrolled10 locationsNCT07217171
Recruiting
Phase 1Phase 2
Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
Unresectable MelanomaMetastatic Cutaneous MelanomaMetastatic Uveal Melanoma
Beijing Biotech36 enrolled1 locationNCT07627698
Recruiting
Phase 1
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Stage IIIA Uterine Corpus Cancer AJCC v8+35 more
M.D. Anderson Cancer Center54 enrolled1 locationNCT05039801
Recruiting
Phase 1Phase 2
A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants
Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus
DualityBio Inc.148 enrolled7 locationsNCT06625671
Recruiting
Phase 1
Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease
Psoriatic Arthritis (PsA)Rheumatoid Arthritis (RA)Psoriasis (PsO)+3 more
Seismic Therapeutic AU Pty Ltd24 enrolled2 locationsNCT07455578
Recruiting
Phase 1Phase 2
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Squamous Cell CarcinomaAdvanced or Metastatic Squamous Non-Small Cell Lung CancerAdvanced Head and Neck Squamous Cell Carcinoma+4 more
Hummingbird Bioscience398 enrolled20 locationsNCT05910827
Recruiting
Phase 1
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma
Merkel Cell CarcinomaCutaneous Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute36 enrolled1 locationNCT04975152
Recruiting
Phase 1
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
Peripheral T Cell LymphomaAnaplastic Large Cell LymphomaMycosis Fungoides+7 more
National Cancer Institute (NCI)60 enrolled1 locationNCT07055477
Recruiting
Phase 1Phase 2
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Advanced Solid TumorNon-small Cell Lung CancerMetastatic Cancer+1 more
Aulos Bioscience, Inc.159 enrolled18 locationsNCT05267626